MAR 25, 2019 10:59 AM PDT

Discovery of Biomarker Target for Melanoma

WRITTEN BY: Nouran Amin

According to a study published in the journal Cancer Research, researchers have discovered a biomarker that could serve as a possible therapeutic target for melanoma. The marker is microphthalmia-associated transcription factor (MITF)—which is is a protein that plays a crictcal role in the maintenance of the melanocyte lineage (cells that make melanin), as well as the differentiation of normal and malignant melanocytes and melanoma cell survival.

Melanoma in skin biopsy with H&E stain — this case may represent superficial spreading melanoma. Credit: Wikipedia/CC BY-SA 3.0

"We have now detected the first useful chemical inhibitor of MITF," said corresponding author Rhoda Alani, MD, the Herbert Mescon Chair of Dermatology at Boston University School of Medicine.

Over the past decade genetic mutations in human melanomas have been extensively examined—regardless, the role of epigenetic alterations in the development and progression of melanomas is still not well understood.

Specifically, scientists discovered that the inhibition of the epigenetic p300 Histone Acetyltransferase (HAT) enzyme stops the growth of human melanoma cells and cells that express the MITF protein are sensitive to this inhibition. The inhibition can hold many broad implications for the treatment of pigmented lesions in the skin which could potentially be used for the topical treatment of hyperpigmentation.

The study opens the doors to the endless pursuit for additional epigenetic approaches to cancers.

"When human melanoma cell lines were evaluated for growth effects using the chemical inhibitor of p300 HAT, the cell lines that were most sensitive to drug treatment were those that expressed high levels of MITF suggesting that MITF expression levels can predict melanoma sensitivity to such therapies," explained Alani, who also is chief of dermatology at Boston Medical Center.

Source: EurekAlert

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
MAY 25, 2021
Cell & Molecular Biology
A simplified high-throughput protein expression system
MAY 25, 2021
A simplified high-throughput protein expression system
Protein synthesis, protein engineering, and synthetic biology researchers can research their protein of interest using e ...
MAY 19, 2021
Drug Discovery & Development
Combination Immunotherapy Shows Promise in Treating HIV
MAY 19, 2021
Combination Immunotherapy Shows Promise in Treating HIV
  Researchers have found that a new combination immunotherapy, alongside antiretroviral therapy (ART), is effective ...
JUL 12, 2021
Health & Medicine
Is Caffeine Good or Bad for Migraines?
JUL 12, 2021
Is Caffeine Good or Bad for Migraines?
The short answer is it's still not certain if caffeine helps or worsens migraines, but chronic consumption of caffei ...
JUL 11, 2021
Drug Discovery & Development
Could Mucus-Based Drugs Replace Antibiotics?
JUL 11, 2021
Could Mucus-Based Drugs Replace Antibiotics?
Researchers from the Copenhagen Center for Glycomics in Denmark have developed a way to produce healthy mucus artificial ...
JUL 15, 2021
Drug Discovery & Development
The genomics of high blood pressure - a road to the future of treatment
JUL 15, 2021
The genomics of high blood pressure - a road to the future of treatment
The human heart begins to beat in utero in the early weeks of development and continues throughout life. In an average l ...
JUL 20, 2021
Technology
Artificial Intelligence Predicts Which Drug Candidates Will Be Successful In Clinical Trials
JUL 20, 2021
Artificial Intelligence Predicts Which Drug Candidates Will Be Successful In Clinical Trials
Researchers are leveraging artificial intelligence and machine learning to help improve the rate at which drugs move suc ...
Loading Comments...